Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices-Reference-Cited by-同舟云学术

Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices

Published:2019-02 Issue:5 Volume:15 Page:459-471
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Whitman Eric D¹,Liu Frank Xiaoqing²,Cao Xiting²,Diede Scott J²,Haiderali Amin²,Abernethy Amy P³

Affiliation:

1. Atlantic Melanoma Center, Atlantic Health System Cancer Care, 100 Madison Ave., Morristown, NJ 07960, USA

2. Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA

3. Flatiron Health, Inc., 233 Spring St, New York, NY 10013, USA

Abstract

Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. Results: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3–23.3). Conclusion: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0620

Reference53 articles.

1. AIM at Melanoma Foundation. Melanoma stats, facts, and figures. www.aimatmelanoma.org/about-melanoma/melanoma-stats-facts-and-figures/.

2. Cutaneous melanoma

3. Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011

4. SEER cancer statistics factsheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html.

5. Noone AM, Howlader N, Krapcho M (Eds). SEER cancer statistics review, 1975–2015 based on November 2017 SEER data submission (2018), National Cancer Institute, MD, USA (2018). https://seer.cancer.gov/csr/1975_2015/.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015–2018 in Greece. The ‘SUMMER’ study: a retrospective multicenter chart review project;Melanoma Research;2023-12-13

2. Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada;Current Oncology;2023-04-13

3. Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma;Future Oncology;2022-04

4. Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma;Current Oncology;2022-03-01

5. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States;JCO Oncology Practice;2022-01